| Year |
Citation |
Score |
| 2023 |
Akgöl K, van Merendonk LN, Barkman HJ, van Balen DE, van den Hoek HL, Klous MG, Hendrikx JJ, Huitema AD, Beijnen JH, Nuijen B. Redispensing of expensive oral anticancer medicines: A practical application. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 10781552231176199. PMID 37192749 DOI: 10.1177/10781552231176199 |
0.413 |
|
| 2022 |
van der Heijden L, van Nuland M, Beijnen J, Huitema A, Dorlo T. A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens. Clinical and Translational Science. PMID 36419385 DOI: 10.1111/cts.13446 |
0.541 |
|
| 2022 |
Embaby A, van Merendonk L, Steeghs N, Beijnen J, Huitema A. Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose? Frontiers in Oncology. 12: 940582. PMID 36185303 DOI: 10.3389/fonc.2022.940582 |
0.38 |
|
| 2021 |
Joosten SEP, Wellenstein M, Koornstra R, van Rossum A, Sanders J, van der Noort V, Ferrandez MC, Harkes R, Mandjes IAM, Rosing H, Huitema A, Beijnen JH, Wesseling J, van Diest PJ, Horlings HM, et al. IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. Npj Breast Cancer. 7: 138. PMID 34671036 DOI: 10.1038/s41523-021-00344-3 |
0.419 |
|
| 2021 |
Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Jóźwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC. A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer. PMID 33539540 DOI: 10.1200/Jco.2019.37.15_Suppl.3118 |
0.6 |
|
| 2020 |
van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen J, Bernards R, Schellens J. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The Oncologist. 26: 290-e545. PMID 33296125 DOI: 10.1002/onco.13631 |
0.583 |
|
| 2020 |
de Jong KA, van Breugel SJ, Hillebrand MJ, Rosing H, Huitema AD, Beijnen JH. Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices. Bioanalysis. PMID 32975434 DOI: 10.4155/bio-2020-0204 |
0.403 |
|
| 2019 |
Arnamo AH, Huitema AD, Beijnen JH, Nuijen B. Use of leftovers of monoclonal antibody products after partial extraction - A microbiological safety study. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155219850297. PMID 31156055 DOI: 10.1177/1078155219850297 |
0.368 |
|
| 2017 |
van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. Jmir Research Protocols. 6: e136. PMID 28705789 DOI: 10.2196/resprot.7790 |
0.367 |
|
| 2017 |
Verheijen RB, Beijnen JH, Schellens JH, Huitema AD, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clinical Pharmacokinetics. PMID 28185218 DOI: 10.1007/S40262-017-0510-Z |
0.594 |
|
| 2016 |
Sawicki E, Verheijen RB, Huitema AD, van Tellingen O, Schellens JH, Nuijen B, Beijnen JH, Steeghs N. Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research. PMID 27864786 DOI: 10.1007/S13346-016-0346-3 |
0.604 |
|
| 2016 |
Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Therapeutic Drug Monitoring. 38: 649-656. PMID 27749781 DOI: 10.1097/Ftd.0000000000000349 |
0.55 |
|
| 2016 |
Yu H, van Erp N, Bins S, Mathijssen RH, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clinical Pharmacokinetics. PMID 27534647 DOI: 10.1007/S40262-016-0443-Y |
0.586 |
|
| 2016 |
Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27470967 DOI: 10.1158/1078-0432.Ccr-16-1255 |
0.606 |
|
| 2016 |
van Erp NP, van Herpen CM, de Wit D, Willemsen A, Burger DM, Huitema AD, Kapiteijn E, Ter Heine R. A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. Clinical Pharmacokinetics. PMID 27299325 DOI: 10.1007/S40262-016-0414-3 |
0.337 |
|
| 2016 |
Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson P, Rosing H, Spiegelstein O, Schellens JH. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors. Investigational New Drugs. PMID 27221729 DOI: 10.1007/S10637-016-0360-9 |
0.623 |
|
| 2016 |
Jacobs BA, Deenen MJ, Pluim D, van Hasselt JG, Krähenbühl MD, van Geel RM, de Vries N, Rosing H, Meulendijks D, Burylo AM, Cats A, Beijnen JH, Huitema AD, Schellens JH. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. British Journal of Clinical Pharmacology. PMID 27161955 DOI: 10.1111/Bcp.13007 |
0.74 |
|
| 2016 |
Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. Cancer Chemotherapy and Pharmacology. PMID 27103124 DOI: 10.1007/S00280-016-3035-5 |
0.539 |
|
| 2016 |
Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. Journal of Clinical Pharmacology. PMID 26918324 DOI: 10.1002/Jcph.728 |
0.576 |
|
| 2016 |
van Geel RM, Hendrikx JJ, Vahl JE, van Leerdam ME, van den Broek D, Huitema AD, Beijnen JH, Schellens JH, Burgers SA. Crizotinib-induced fatal fulminant liver failure. Lung Cancer (Amsterdam, Netherlands). 93: 17-9. PMID 26898609 DOI: 10.1016/J.Lungcan.2015.12.010 |
0.519 |
|
| 2016 |
Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. European Journal of Cancer (Oxford, England : 1990). 54: 120-130. PMID 26761784 DOI: 10.1016/J.Ejca.2015.10.013 |
0.761 |
|
| 2016 |
Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers. 8. PMID 26729170 DOI: 10.3390/Cancers8010006 |
0.58 |
|
| 2015 |
Derissen EJ, Jacobs BA, Huitema AD, Rosing H, Schellens JH, Beijnen JH. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment. British Journal of Clinical Pharmacology. PMID 26718616 DOI: 10.1111/Bcp.12877 |
0.555 |
|
| 2015 |
Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD. Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. Bioanalysis. PMID 26652864 DOI: 10.4155/Bio.15.235 |
0.566 |
|
| 2015 |
Yu H, Hendrikx JJ, Rottenberg S, Schellens JH, Beijnen JH, Huitema AD. Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. The Aaps Journal. PMID 26603889 DOI: 10.1208/S12248-015-9838-1 |
0.57 |
|
| 2015 |
Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. PMID 26547132 DOI: 10.1016/J.Ctrv.2015.10.008 |
0.545 |
|
| 2015 |
Meulendijks D, Lassen U, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker D, Hansen A, Simcox ME, Schostack K, Bottino D, Zhong H, Roessler M, Vega-Harring S, Jarutat T, et al. Exposure and Tumor Fn14 expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-positive Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446946 DOI: 10.1158/1078-0432.Ccr-15-1506 |
0.363 |
|
| 2015 |
Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, Huitema AD. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research & Perspectives. 3: e00131. PMID 26038706 DOI: 10.1002/Prp2.131 |
0.551 |
|
| 2015 |
de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. Clinical Pharmacokinetics. 54: 797-810. PMID 25940823 DOI: 10.1007/S40262-015-0273-3 |
0.472 |
|
| 2015 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy". Biomed Research International. 2015: 124035. PMID 25922829 DOI: 10.1155/2015/124035 |
0.76 |
|
| 2015 |
Lankheet NA, Schaake EE, Burgers SA, van Pel R, Beijnen JH, Huitema AD, Klomp H. Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy. Clinical Lung Cancer. 16: 320-4. PMID 25682545 DOI: 10.1016/J.Cllc.2014.12.012 |
0.41 |
|
| 2015 |
Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. British Journal of Clinical Pharmacology. PMID 25677219 DOI: 10.1111/Bcp.12606 |
0.574 |
|
| 2015 |
Meulendijks D, Khan S, Koks CH, Huitema AD, Schellens JH, Beijnen JH. Baclofen overdose treated with continuous venovenous hemofiltration. European Journal of Clinical Pharmacology. 71: 357-61. PMID 25567218 DOI: 10.1007/S00228-014-1802-Y |
0.535 |
|
| 2015 |
Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. British Journal of Clinical Pharmacology. 79: 809-19. PMID 25393890 DOI: 10.1111/Bcp.12550 |
0.767 |
|
| 2015 |
Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investigational New Drugs. 33: 233-40. PMID 25377392 DOI: 10.1007/S10637-014-0181-7 |
0.612 |
|
| 2014 |
Crombag MR, de Vries Schultink AH, Schellens JH, Beijnen JH, Huitema AD. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study. Drugs & Aging. 31: 737-47. PMID 25216600 DOI: 10.1007/S40266-014-0207-Z |
0.538 |
|
| 2014 |
van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD. Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation. Pediatric Blood & Cancer. 61: 2223-9. PMID 25175364 DOI: 10.1002/Pbc.25198 |
0.759 |
|
| 2014 |
Opdam FL, Huitema AD, Beijnen JH, Schellens JH. [Hyperglycaemia during treatment with everolimus]. Nederlands Tijdschrift Voor Geneeskunde. 158: A7544. PMID 25115206 |
0.534 |
|
| 2014 |
van Hasselt JG, Schellens JH, Beijnen JH, Huitema AD. Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error. Investigational New Drugs. 32: 913-27. PMID 24788562 DOI: 10.1007/S10637-014-0103-8 |
0.763 |
|
| 2014 |
Hendrikx JJ, Lagas JS, Daling R, Hooijberg JH, Schellens JH, Beijnen JH, Brandjes DP, Huitema AD. Severe lactic acidosis in a diabetic patient after ethanol abuse and floor cleaner intake. Basic & Clinical Pharmacology & Toxicology. 115: 472-5. PMID 24717115 DOI: 10.1111/Bcpt.12251 |
0.507 |
|
| 2014 |
ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, Huitema AD. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. British Journal of Clinical Pharmacology. 78: 572-86. PMID 24697814 DOI: 10.1111/Bcp.12388 |
0.445 |
|
| 2014 |
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. Biomed Research International. 2014: 897216. PMID 24672799 DOI: 10.1155/2014/897216 |
0.764 |
|
| 2014 |
Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clinical Pharmacokinetics. 53: 305-25. PMID 24566736 DOI: 10.1007/S40262-014-0137-2 |
0.6 |
|
| 2014 |
Meulenaar J, Keizer RJ, Beijnen JH, Schellens JH, Huitema AD, Nuijen B. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling. Journal of Pharmaceutical Sciences. 103: 478-84. PMID 24311366 DOI: 10.1002/Jps.23779 |
0.552 |
|
| 2014 |
Lankheet NA, Knapen LM, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care. Therapeutic Drug Monitoring. 36: 326-34. PMID 24305627 DOI: 10.1097/Ftd.0000000000000004 |
0.57 |
|
| 2014 |
Frederix GW, van Hasselt JG, Schellens JH, Hövels AM, Raaijmakers JA, Huitema AD, Severens JL. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 32: 47-61. PMID 24263964 DOI: 10.1007/S40273-013-0106-X |
0.718 |
|
| 2014 |
Kloth JS, Klümpen HJ, Yu H, Eechoute K, Samer CF, Kam BL, Huitema AD, Daali Y, Zwinderman AH, Balakrishnar B, Bennink RJ, Wong M, Schellens JH, Mathijssen RH, Gurney H. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clinical Pharmacokinetics. 53: 261-9. PMID 24234588 DOI: 10.1007/S40262-013-0111-4 |
0.435 |
|
| 2014 |
Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH. Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. Current Clinical Pharmacology. 9: 139-47. PMID 24219005 DOI: 10.2174/1574884708666131111193403 |
0.557 |
|
| 2013 |
Moes JJ, Stuurman FE, Hendrikx JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B. Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. Drug Delivery and Translational Research. 3: 243-51. PMID 25788133 DOI: 10.1007/S13346-012-0127-6 |
0.621 |
|
| 2013 |
Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. Bmc Cancer. 13: 612. PMID 24373320 DOI: 10.1186/1471-2407-13-612 |
0.565 |
|
| 2013 |
Lankheet NA, Huitema AD, Mallo H, Adriaansz S, Haanen JB, Schellens JH, Beijnen JH, Blank CU. The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome. European Journal of Clinical Pharmacology. 69: 2065-72. PMID 23995862 DOI: 10.1007/S00228-013-1579-4 |
0.566 |
|
| 2013 |
Leijen S, Veltkamp SA, Huitema AD, van Werkhoven E, Beijnen JH, Schellens JH. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer. Gynecologic Oncology. 130: 511-7. PMID 23665458 DOI: 10.1016/J.Ygyno.2013.05.001 |
0.613 |
|
| 2013 |
van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. British Journal of Clinical Pharmacology. 76: 412-24. PMID 23601153 DOI: 10.1111/Bcp.12143 |
0.788 |
|
| 2013 |
van Hasselt JG, van Eijkelenburg NK, Huitema AD, Schellens JH, Schouten-van Meeteren AY. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrobial Agents and Chemotherapy. 57: 2878-81. PMID 23571545 DOI: 10.1128/Aac.00068-13 |
0.729 |
|
| 2013 |
Frederix GW, van Hasselt JG, Severens JL, Hövels AM, Huitema AD, Raaijmakers JA, Schellens JH. Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 780-92. PMID 23515213 DOI: 10.1177/0272989X13476763 |
0.7 |
|
| 2013 |
Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof-of-concept study. Antiviral Therapy. 18: 821-5. PMID 23234680 DOI: 10.3851/Imp2501 |
0.469 |
|
| 2013 |
Milojkovic Kerklaan B, Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer Chemotherapy and Pharmacology. 71: 53-62. PMID 23053259 DOI: 10.1007/s00280-012-1972-1 |
0.594 |
|
| 2013 |
Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JH. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British Journal of Clinical Pharmacology. 75: 507-15. PMID 22803519 DOI: 10.1111/J.1365-2125.2012.04381.X |
0.621 |
|
| 2012 |
Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. 83: 87-94. PMID 23085332 DOI: 10.1016/j.ejpb.2012.09.016 |
0.597 |
|
| 2012 |
Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clinical Pharmacokinetics. 51: 607-17. PMID 22804749 DOI: 10.1007/Bf03261934 |
0.631 |
|
| 2012 |
Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses. The Aaps Journal. 14: 601-11. PMID 22648902 DOI: 10.1208/S12248-012-9373-2 |
0.527 |
|
| 2012 |
Dorlo TP, Huitema AD, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy. 56: 3864-72. PMID 22585212 DOI: 10.1128/Aac.00292-12 |
0.439 |
|
| 2012 |
van Hasselt JG, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema AD. Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. Journal of Palliative Care. 28: 60-1. PMID 22582474 |
0.741 |
|
| 2012 |
Dorlo TP, Balasegaram M, Lima MA, de Vries PJ, Beijnen JH, Huitema AD. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine. The Journal of Antimicrobial Chemotherapy. 67: 1996-2004. PMID 22577099 DOI: 10.1093/Jac/Dks164 |
0.486 |
|
| 2012 |
Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. The Journal of Antimicrobial Chemotherapy. 67: 1211-6. PMID 22302563 DOI: 10.1093/Jac/Dks011 |
0.469 |
|
| 2012 |
Keizer RJ, Gupta A, Shumaker R, Beijnen JH, Schellens JH, Huitema AD. Model-based treatment optimization of a novel VEGFR inhibitor. British Journal of Clinical Pharmacology. 74: 315-26. PMID 22295876 DOI: 10.1111/J.1365-2125.2012.04197.X |
0.609 |
|
| 2012 |
Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, Beijnen JH. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 313-21. PMID 22041109 DOI: 10.1124/Dmd.111.042762 |
0.601 |
|
| 2012 |
Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 118: 2466-75. PMID 22031394 DOI: 10.1002/Cncr.26562 |
0.552 |
|
| 2012 |
Joerger M, Ferreri AJ, Krähenbühl S, Schellens JH, Cerny T, Zucca E, Huitema AD. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. British Journal of Clinical Pharmacology. 73: 240-7. PMID 21838788 DOI: 10.1111/J.1365-2125.2011.04084.X |
0.472 |
|
| 2012 |
Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Investigational New Drugs. 30: 1519-30. PMID 21626115 DOI: 10.1007/S10637-011-9694-5 |
0.594 |
|
| 2012 |
Keizer RJ, Budde IK, Sprengers PF, Levi M, Beijnen JH, Huitema AD. Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor. Journal of Clinical Pharmacology. 52: 204-13. PMID 21263014 DOI: 10.1177/0091270010394446 |
0.5 |
|
| 2011 |
Lankheet NA, Blank CU, Mallo H, Adriaansz S, Rosing H, Schellens JH, Huitema AD, Beijnen JH. Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. Journal of Analytical Toxicology. 35: 558-65. PMID 22004675 DOI: 10.1093/Anatox/35.8.558 |
0.563 |
|
| 2011 |
Tran L, Baars J, Damen C, Beijnen J, Huitema A. Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab. Journal of Pharmaceutical and Biomedical Analysis. 56: 609-14. PMID 21723685 DOI: 10.1016/J.Jpba.2011.05.026 |
0.37 |
|
| 2011 |
van den Broek MP, Huitema AD, van Hasselt JG, Groenendaal F, Toet MC, Egberts TC, de Vries LS, Rademaker CM. Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures. Clinical Pharmacokinetics. 50: 461-9. PMID 21651313 DOI: 10.2165/11589160-000000000-00000 |
0.729 |
|
| 2011 |
Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis. 3: 1093-7. PMID 21585304 DOI: 10.4155/Bio.11.72 |
0.488 |
|
| 2011 |
ter Heine R, Van Waterschoot RA, Keizer RJ, Beijnen JH, Schinkel AH, Huitema AD. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. Journal of Pharmaceutical Sciences. 100: 2508-15. PMID 21491455 DOI: 10.1002/Jps.22457 |
0.408 |
|
| 2011 |
Lankheet NA, Padberg RD, de Kluiver EM, Wilhelm AJ, van Woensel JB, Beijnen JH, Huitema AD. Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels. Journal of Child and Adolescent Psychopharmacology. 21: 93-5. PMID 21288123 DOI: 10.1089/Cap.2010.0110 |
0.352 |
|
| 2011 |
Keizer RJ, Schellens JH, Beijnen JH, Huitema AD. Pharmacodynamic biomarkers in model-based drug development in oncology. Current Clinical Pharmacology. 6: 30-40. PMID 21235464 DOI: 10.2174/157488411794941368 |
0.578 |
|
| 2011 |
Lagas JS, Wagenaar JF, Huitema AD, Hillebrand MJ, Koks CH, Gerdes VE, Brandjes DP, Beijnen JH. Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: case report and a review of the literature. Human & Experimental Toxicology. 30: 1399-403. PMID 21056950 DOI: 10.1177/0960327110388962 |
0.41 |
|
| 2011 |
Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Computer Methods and Programs in Biomedicine. 101: 72-9. PMID 20627442 DOI: 10.1016/J.Cmpb.2010.04.018 |
0.509 |
|
| 2011 |
Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational New Drugs. 29: 984-95. PMID 20449627 DOI: 10.1007/S10637-010-9437-Z |
0.58 |
|
| 2010 |
Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. Journal of Pharmacokinetics and Pharmacodynamics. 37: 347-63. PMID 20652729 DOI: 10.1007/S10928-010-9164-2 |
0.591 |
|
| 2010 |
Goey AK, Schellens JH, Beijnen JH, Huitema AD. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. Nederlands Tijdschrift Voor Geneeskunde. 154: A1155. PMID 20619024 |
0.541 |
|
| 2010 |
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 49: 493-507. PMID 20608753 DOI: 10.2165/11531280-000000000-00000 |
0.559 |
|
| 2010 |
Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. British Journal of Clinical Pharmacology. 69: 475-83. PMID 20573083 DOI: 10.1111/J.1365-2125.2010.03634.X |
0.535 |
|
| 2010 |
Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. British Journal of Clinical Pharmacology. 69: 465-74. PMID 20573082 DOI: 10.1111/J.1365-2125.2010.03621.X |
0.615 |
|
| 2010 |
Ter Heine R, Rosing H, Beijnen JH, Huitema AD. A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 48: 1153-5. PMID 20482447 DOI: 10.1515/Cclm.2010.225 |
0.405 |
|
| 2010 |
Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Investigational New Drugs. 28: 61-75. PMID 19198760 DOI: 10.1007/S10637-008-9216-2 |
0.599 |
|
| 2009 |
Tran L, Beijnen JH, Huitema AD. The preparation of radiolabeled monoclonal antibodies for human use. Human Antibodies. 18: 145-56. PMID 19996529 DOI: 10.3233/Hab-2009-0211 |
0.377 |
|
| 2009 |
Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, Schellens JH. Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature. The Oncologist. 14: 944-8. PMID 19726456 DOI: 10.1634/Theoncologist.2009-0111 |
0.611 |
|
| 2009 |
Oostendorp RL, Huitema A, Rosing H, Jansen RS, Ter Heine R, Keessen M, Beijnen JH, Schellens JH. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4228-33. PMID 19509162 DOI: 10.1158/1078-0432.Ccr-08-2944 |
0.565 |
|
| 2009 |
Ter Heine R, Huitema AD, Jansen RS, Smits PH, van Gorp EC, Wagenaar JF, Beijnen JH, Mulder JW. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. Antiviral Therapy. 14: 299-301. PMID 19430105 |
0.397 |
|
| 2009 |
Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncologica (Stockholm, Sweden). 48: 832-41. PMID 19308757 DOI: 10.1080/02841860902806609 |
0.576 |
|
| 2009 |
Tran L, Baars JW, Maessen HJ, Hoefnagel CA, Beijnen JH, Huitema AD. A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy. Cancer Biotherapy & Radiopharmaceuticals. 24: 103-10. PMID 19243252 DOI: 10.1089/Cbr.2008.0538 |
0.446 |
|
| 2009 |
Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. Journal of Pharmacokinetics and Pharmacodynamics. 36: 39-62. PMID 19199010 DOI: 10.1007/S10928-009-9111-2 |
0.61 |
|
| 2009 |
Keizer RJ, Zamacona MK, Jansen M, Critchley D, Wanders J, Beijnen JH, Schellens JH, Huitema AD. Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820. Investigational New Drugs. 27: 140-52. PMID 18712503 DOI: 10.1007/S10637-008-9164-X |
0.603 |
|
| 2008 |
ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, Huitema AD. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antiviral Therapy. 13: 779-87. PMID 18839779 |
0.475 |
|
| 2008 |
Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. Bmc Clinical Pharmacology. 8: 7. PMID 18796166 DOI: 10.1186/1472-6904-8-7 |
0.58 |
|
| 2008 |
Zandvliet AS, Schellens JH, Dittrich C, Wanders J, Beijnen JH, Huitema AD. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. British Journal of Clinical Pharmacology. 66: 485-97. PMID 18637887 DOI: 10.1111/J.1365-2125.2008.03230.X |
0.62 |
|
| 2008 |
Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clinical Pharmacokinetics. 47: 487-513. PMID 18611060 DOI: 10.2165/00003088-200847080-00001 |
0.618 |
|
| 2008 |
Brouwers EE, Huitema AD, Schellens JH, Beijnen JH. The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. Anti-Cancer Drugs. 19: 621-30. PMID 18525322 DOI: 10.1097/Cad.0B013E3282Ffd6A4 |
0.508 |
|
| 2008 |
Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrobial Agents and Chemotherapy. 52: 2855-60. PMID 18519729 DOI: 10.1128/Aac.00014-08 |
0.493 |
|
| 2007 |
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, et al. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical Pharmacokinetics. 46: 1051-68. PMID 18027989 DOI: 10.2165/00003088-200746120-00005 |
0.63 |
|
| 2007 |
Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6410-8. PMID 17975154 DOI: 10.1158/1078-0432.Ccr-07-0064 |
0.591 |
|
| 2007 |
ter Heine R, Alderden-Los CG, Rosing H, Hillebrand MJ, van Gorp EC, Huitema AD, Beijnen JH. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 21: 2505-14. PMID 17610214 DOI: 10.1002/Rcm.3119 |
0.48 |
|
| 2007 |
Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JH. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2970-6. PMID 17504998 DOI: 10.1158/1078-0432.Ccr-06-2978 |
0.556 |
|
| 2007 |
Sankatsing SU, Cornelissen M, Kloosterboer N, Crommentuyn KM, Bosch TM, Mul FP, Jurriaans S, Huitema AD, Beijnen JH, Lange JM, Prins JM, Schuitemaker H. Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. Aids Research and Human Retroviruses. 23: 19-27. PMID 17263628 DOI: 10.1089/Aid.2006.0027 |
0.384 |
|
| 2006 |
Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Current Clinical Pharmacology. 1: 109-18. PMID 18666382 DOI: 10.2174/157488406775268219 |
0.482 |
|
| 2006 |
Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5786-93. PMID 17020985 DOI: 10.1158/1078-0432.Ccr-05-2649 |
0.585 |
|
| 2006 |
Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. Journal of Pharmacokinetics and Pharmacodynamics. 33: 543-70. PMID 16946998 DOI: 10.1007/S10928-006-9021-5 |
0.593 |
|
| 2006 |
Rook EJ, Huitema AD, van den Brink W, Hillebrand MJ, van Ree JM, Beijnen JH. Screening for illicit heroin use in patients in a heroin-assisted treatment program. Journal of Analytical Toxicology. 30: 390-4. PMID 16872571 DOI: 10.1093/Jat/30.6.390 |
0.434 |
|
| 2006 |
Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. Biomedical Chromatography : Bmc. 20: 671-3. PMID 16799929 DOI: 10.1002/Bmc.667 |
0.56 |
|
| 2006 |
Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. The Pediatric Infectious Disease Journal. 25: 538-43. PMID 16732153 DOI: 10.1097/01.Inf.0000215242.70300.95 |
0.698 |
|
| 2006 |
Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2150-7. PMID 16609028 DOI: 10.1158/1078-0432.Ccr-05-2069 |
0.608 |
|
| 2006 |
Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Population pharmacokinetics of heroin and its major metabolites. Clinical Pharmacokinetics. 45: 401-17. PMID 16584286 DOI: 10.2165/00003088-200645040-00005 |
0.476 |
|
| 2006 |
Zandvliet AS, Copalu W, Schellens JH, Beijnen JH, Huitema AD. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1041-6. PMID 16565173 DOI: 10.1124/Dmd.105.008326 |
0.548 |
|
| 2006 |
Rook EJ, van Ree JM, van den Brink W, Hillebrand MJ, Huitema AD, Hendriks VM, Beijnen JH. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic & Clinical Pharmacology & Toxicology. 98: 86-96. PMID 16433897 DOI: 10.1111/J.1742-7843.2006.Pto_233.X |
0.505 |
|
| 2006 |
Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH, Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomedical Chromatography : Bmc. 20: 72-6. PMID 15954163 DOI: 10.1002/Bmc.530 |
0.565 |
|
| 2005 |
Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Hiv Clinical Trials. 6: 254-61. PMID 16306032 DOI: 10.1310/B5Vu-Fu5F-Qnwc-Udck |
0.487 |
|
| 2005 |
Kappelhoff BS, Huitema AD, Sankatsing SU, Meenhorst PL, Van Gorp EC, Mulder JW, Prins JM, Beijnen JH. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. British Journal of Clinical Pharmacology. 60: 276-86. PMID 16120066 DOI: 10.1111/J.1365-2125.2005.02436.X |
0.55 |
|
| 2005 |
Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antiviral Therapy. 10: 489-98. PMID 16038474 |
0.435 |
|
| 2005 |
Kappelhoff BS, Huitema AD, Yalvaç Z, Prins JM, Mulder JW, Meenhorst PL, Beijnen JH. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clinical Pharmacokinetics. 44: 849-61. PMID 16029069 DOI: 10.2165/00003088-200544080-00006 |
0.512 |
|
| 2005 |
Kappelhoff BS, Huitema AD, Mairuhu AT, Schellens JH, Beijnen JH. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Anti-Cancer Drugs. 16: 627-30. PMID 15930890 DOI: 10.1097/00001813-200507000-00006 |
0.609 |
|
| 2005 |
Crommentuyn KM, Huitema AD, Brinkman K, van der Ende ME, de Wolf F, Beijnen JH. Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. Journal of Acquired Immune Deficiency Syndromes (1999). 39: 249-50. PMID 15905743 |
0.466 |
|
| 2005 |
van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investigational New Drugs. 23: 225-34. PMID 15868378 DOI: 10.1007/S10637-005-6730-3 |
0.758 |
|
| 2005 |
Klous MG, Huitema AD, Rook EJ, Hillebrand MJ, Hendriks VM, Van den Brink W, Beijnen JH, Van Ree JM. Pharmacokinetic comparison of two methods of heroin smoking: 'chasing the dragon' versus the use of a heating device. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 15: 263-9. PMID 15820414 DOI: 10.1016/J.Euroneuro.2004.12.001 |
0.395 |
|
| 2005 |
Kappelhoff BS, Huitema AD, Beijnen JH. Should non-nucleoside reverse transcriptase inhibitors be combined? Drugs in R&D. 6: 61-9. PMID 15777100 DOI: 10.2165/00126839-200506020-00001 |
0.482 |
|
| 2005 |
Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antiviral Therapy. 10: 145-55. PMID 15751772 |
0.467 |
|
| 2005 |
Kappelhoff BS, Huitema AD, Crommentuyn KM, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, Beijnen JH. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. British Journal of Clinical Pharmacology. 59: 174-82. PMID 15676039 DOI: 10.1111/J.1365-2125.2004.02241.X |
0.543 |
|
| 2005 |
Zandvliet AS, Huitema AD, de Jonge ME, den Hoed R, Sparidans RW, Hendriks VM, van den Brink W, van Ree JM, Beijnen JH. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. Basic & Clinical Pharmacology & Toxicology. 96: 71-9. PMID 15667599 DOI: 10.1111/J.1742-7843.2005.Pto960111.X |
0.515 |
|
| 2004 |
Crommentuyn KM, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antiviral Therapy. 9: 779-85. PMID 15535416 |
0.51 |
|
| 2004 |
Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clinical Pharmacokinetics. 43: 845-53. PMID 15509183 DOI: 10.2165/00003088-200443130-00002 |
0.519 |
|
| 2004 |
Sankatsing SU, Hoggard PG, Huitema AD, Sparidans RW, Kewn S, Crommentuyn KM, Lange JM, Beijnen JH, Back DJ, Prins JM. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clinical Pharmacokinetics. 43: 823-32. PMID 15355127 DOI: 10.2165/00003088-200443120-00004 |
0.454 |
|
| 2004 |
de Maat MM, Nellen JF, Huitema AD, Wit FW, Mulder JW, Prins JM, Beijnen JH. Race is not associated with nevirapine pharmacokinetics. Therapeutic Drug Monitoring. 26: 456-8. PMID 15257078 DOI: 10.1097/00007691-200408000-00018 |
0.49 |
|
| 2004 |
Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 38: e73-5. PMID 15095234 DOI: 10.1086/382675 |
0.565 |
|
| 2004 |
de Jonge ME, van den Bongard HJ, Huitema AD, Mathôt RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, Schellens JH. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2237-44. PMID 15073098 DOI: 10.1158/1078-0432.Ccr-03-0060 |
0.761 |
|
| 2004 |
Huitema AD, Kuiper RA, Meenhorst PL, Mulder JW, Beijnen JH. Photophobia in a patient with high indinavir plasma concentrations. Therapeutic Drug Monitoring. 25: 735-7. PMID 14639061 DOI: 10.1097/00007691-200312000-00013 |
0.493 |
|
| 2004 |
Kappelhoff BS, Rosing H, Huitema AD, Beijnen JH. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 792: 353-62. PMID 12860043 DOI: 10.1016/S1570-0232(03)00325-8 |
0.493 |
|
| 2003 |
de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, Beijnen JH. Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals. Clinical Drug Investigation. 23: 629-37. PMID 17535078 DOI: 10.2165/00044011-200323100-00002 |
0.455 |
|
| 2003 |
de Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, van Gorp EC, Huitema AD, Beijnen JH. Incidence and risk factors for nevirapine-associated rash. European Journal of Clinical Pharmacology. 59: 457-62. PMID 12920493 DOI: 10.1007/S00228-003-0613-3 |
0.435 |
|
| 2003 |
de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clinical Pharmacokinetics. 42: 599-605. PMID 12793844 DOI: 10.2165/00003088-200342060-00009 |
0.43 |
|
| 2003 |
de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Mairuhu AT, Beijnen JH. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care. Therapeutic Drug Monitoring. 25: 367-73. PMID 12766566 DOI: 10.1097/00007691-200306000-00018 |
0.496 |
|
| 2003 |
Koks CH, Huitema AD, Kroon ED, Chuenyam T, Sparidans RW, Lange JM, Beijnen JH. Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. Therapeutic Drug Monitoring. 25: 229-33. PMID 12657919 DOI: 10.1097/00007691-200304000-00014 |
0.449 |
|
| 2003 |
de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clinical Pharmacokinetics. 42: 223-82. PMID 12603174 DOI: 10.2165/00003088-200342030-00002 |
0.443 |
|
| 2003 |
Boelaert JR, Dom GM, Huitema AD, Beijnen JH, Lange JM. The boosting of didanosine by allopurinol permits a halving of the didanosine dosage. Aids (London, England). 16: 2221-3. PMID 12409745 DOI: 10.1097/00002030-200211080-00016 |
0.428 |
|
| 2003 |
de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. British Journal of Clinical Pharmacology. 54: 378-85. PMID 12392585 DOI: 10.1046/J.1365-2125.2002.01657.X |
0.46 |
|
| Show low-probability matches. |
